Home > Insider Trading > Filing (0001209191-19-017738)

Filing Details

Accession Number:: 0001209191-19-017738
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-03-07 16:06:55
Reporting Period:: 2019-03-05

Accepted Time:: 2019-03-07 16:06:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581956	Scott Biller	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-03-05	428	$31.64	26,939	No	4	M	Direct
Common Stock	Acquisiton	2019-03-05	2,572	$39.76	29,511	No	4	M	Direct
Common Stock	Disposition	2019-03-05	200	$66.45	29,311	No	4	S	Direct
Common Stock	Disposition	2019-03-05	2,600	$67.73	26,711	No	4	S	Direct
Common Stock	Disposition	2019-03-05	200	$68.22	26,511	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2019-03-05	428	$0.00	428	$31.64
Common Stock	Stock option (right to buy)	Disposition	2019-03-05	2,572	$0.00	2,572	$39.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
11,354		2024-03-04	No	4	M	Direct
42,648		2026-02-15	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	53,059	Indirect	See footnote

Footnotes

This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $66.05 to $66.85. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.14 to $68.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.14 to $68.30. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.